Please login to the form below

Not currently logged in
Email:
Password:

Helsinn Therapeutics names Paul Rittman as CEO

He replaces William Mann, who stepped down on 28 February

Helsinn, a Swiss pharmaceutical group focused on cancer care products, has appointed Paul Rittman as its new chief executive officer.

Rittman, who succeeds William Mann, takes up his new role on 5 March and has pharmaceutical industry experience from previous commercial and general management roles.

Riccardo Bragila, vice chairman and chief executive officer for Helsinn Group, said: “I am delighted to welcome aboard Paul Rittman, who has over 30 years’ experience in pharmaceutical sales and marketing with oncology and across a range of disease areas in North America.

“I am sure his expertise, experience and network will prove invaluable in this key commercial moment for the Helsinn Group.”

Rittman most recently served as senior vice president and general manager, US oncology, leading Teva Pharmaceuticals’ oncology activities for its branded products operations.

Prior to his time at Teva, he also held a number of other senior commercial roles at Intrabiotics and Aventis.

Rittman said: “I have always been impressed with Helsinn’s core values of quality, integrity and respect and so I am delighted to be joining at this time.

“Helsinn is an international pharmaceutical business strongly committed to growth through investing in oncology while working to improve the everyday lives of people with cancer.”

1st March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics